OS Therapies (NYSEAMERICAN:OSTX) Trading Down 4.7% – Here’s What Happened

OS Therapies Incorporated (NYSEAMERICAN:OSTX) shares were down 4.7% during trading on Wednesday . The company traded as low as $1.80 and last traded at $1.81. Approximately 576,321 shares were traded during mid-day trading, a decline of 8% from the average daily volume of 626,275 shares. The stock had previously closed at $1.90.

Analysts Set New Price Targets

Several equities research analysts have issued reports on OSTX shares. Zacks Research raised OS Therapies from a “strong sell” rating to a “hold” rating in a research note on Thursday, June 4th. Lake Street Capital decreased their price target on OS Therapies from $14.00 to $13.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Finally, D. Boral Capital reiterated a “buy” rating and set a $20.00 price target on shares of OS Therapies in a report on Thursday, April 30th. Two research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $16.50.

OS Therapies Stock Performance

The business’s 50 day moving average price is $1.79 and its 200-day moving average price is $1.55. The firm has a market capitalization of $84.18 million, a PE ratio of -1.75 and a beta of -0.83.

OS Therapies (NYSEAMERICAN:OSTX) last issued its quarterly earnings data on Monday, May 18th. The company reported ($0.27) EPS for the quarter. As a group, analysts anticipate that OS Therapies Incorporated will post -0.84 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in OSTX. Susquehanna International Group LLP acquired a new stake in shares of OS Therapies in the third quarter valued at $29,000. Jane Street Group LLC acquired a new position in OS Therapies during the 4th quarter worth about $39,000. Mercer Global Advisors Inc. ADV acquired a new position in OS Therapies during the 3rd quarter worth about $40,000. Bridgeway Capital Management LLC purchased a new position in OS Therapies during the 2nd quarter valued at about $47,000. Finally, XTX Topco Ltd purchased a new position in OS Therapies during the 2nd quarter valued at about $63,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.